Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France

Clicks: 462
ID: 110586
2003
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
The rates of PAEs and musculoskeletal PAEs were higher for the FQ group than the control group. This observation supports the American Academy of Pediatrics statement restricting off-label FQ use in pediatric patients to second-line treatment in a limited number of situations.
Reference Key
m2003pediatricsfluoroquinolone Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Chalumeau M;Tonnelier S;D'Athis P;Tréluyer JM;Gendrel D;Bréart G;Pons G; ;;
Journal pediatrics
Year 2003
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/12777590
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't female male adolescent Child Infant Drug Administration Schedule Comparative Study Prospective Studies preschool risk factors Clinical Trial Multicenter Study anti-bacterial agents / therapeutic use Cohort Studies pmid:12777590 doi:10.1542/peds.111.6.e714 controlled clinical trial martin chalumeau sylvie tonnelier pediatric fluoroquinolone safety study investigators anti-bacterial agents / adverse effects cystic fibrosis / complications cystic fibrosis / pathology fluoroquinolones / adverse effects* fluoroquinolones / therapeutic use france multivariate analysis musculoskeletal diseases / chemically induced respiratory tract infections / complications respiratory tract infections / drug therapy respiratory tract infections / prevention & control sinusitis / complications sinusitis / drug therapy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.